July 2012

FDA approved new COPD drug

  • Tue, 07/24/2012 - 12:50pm

The U.S.

What is a clinical trial?

  • Mon, 07/23/2012 - 3:13pm

With all the stories in the news about the U.S. Food and Drug Administration approving various pharmaceutical drugs, we thought you might have a few questions. For instance:

Afinitor approved for breast cancer treatment

  • Mon, 07/23/2012 - 2:41pm

Last Friday, the U.S.

Popular MS treatment may not prevent disability

  • Thu, 07/19/2012 - 3:54pm

A recent study indicates that interferon beta, the most common treatment for multiple sclerosis (MS), may not stop patients from developing the permanent disabilities the incurable autoimmune disea

New polypill reduces cholesterol and heart risk for people over 50

  • Thu, 07/19/2012 - 3:15pm

A new polypill aimed at everyone over age 50

FDA approves HIV-prevention drug

  • Wed, 07/18/2012 - 1:45pm

Adults who do not have HIV but are at high risk of infection are now able to take an FDA-approved medication to decrease the risk of the virus being sexually transmitted.

AstraZeneca blood thinner undergoes trials

  • Wed, 07/18/2012 - 10:45am

In a new international clinical trial, AstraZeneca PLC will compare its blood thinner, Brilinta, to clopidogrel, the generic form of popular blood thinner Plavix.

Buying drugs online is risky business

  • Mon, 07/16/2012 - 3:39pm

Last January, drugs.com published a story about the possible dangers of purchasing over-the-counter medications online. That story said that drugs bought from an online retailer may be:

Propecia impact may be permanent

  • Mon, 07/16/2012 - 12:30pm

In April, WebMD reported that hair growth drug Propecia would soon bear new labels warning of a potential decrease in the desire to have sex, an inability to ejaculate, and an inability to have an

Lawsuits force Johnson & Johnson to work as a team

  • Thu, 07/12/2012 - 3:12pm

Johnson & Johnson’s corporate structure fell under scrutiny in 2010 after contamination and faulty labels led to the recall of over 40 medications, Bloomberg reported yesterday.

Pages